The specificity of antisense approaches is much debated and has hampered their development for clinical therapeutics. In the August 14 Proceedings of the National Academy of Sciences, Yee Cho and ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide (ASO) therapy targeting a single, undisclosed central nervous system ...